Search for Clinical Trial Results

Sponsored By

Richter Syndrome - 14 Studies Found

Status Study
Recruiting Study Name: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter's Syndrome
Condition: Richter Syndrome
Date: 2017-02-10
Interventions:
  • Drug: Venetoclax Venetoclax is
Recruiting Study Name: Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome
Condition: Richter's Syndrome
Date: 2010-07-22
Interventions: Drug: Ofatumumab 1000mg vials (50ml @ 20mg/ml), or 100mg v
Not yet recruiting Study Name: Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
Condition: Richter Syndrome
Date: 2017-04-04
Interventions:
  • Drug: Obinutuzumab 100 mg on d
Not yet recruiting Study Name: Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome
Condition:
  • Richter's Syndrome
  • CLL

Date: 2017-04-10
Interventions: Drug: Obinutuzumab, lenalidomide, HDMP

Recruiting Study Name: Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Condition:
  • Mediastinal Large B-cell Lymphoma
  • Richter Syndrome

Date: 2015-10-14
Interventions: Biological: Pembrolizumab IV infusion Other Names:
Terminated Study Name: Selinexor in Initial or Relapsed/Refractory Richter's Transformation
Condition: Richter's Transformation
Date: 2014-05-13
Interventions: Drug: selinexor 60 mg, may be increased to 80 mg after Cycle 1
Terminated Study Name: PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
Condition: Richter's Transformation
Date: 2015-02-26
Interventions: Drug: PNT2258
Not yet recruiting Study Name: Study of Blinatumomab in Richter Transformation
Condition:
  • Hematopoietic/Lymphoid Cancer
  • Richter's Transformation
    • Date: 2017-04-14
    Interventions:
    • Drug: Blinatumomab

Not yet recruiting Study Name: Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter`s Transformation Requiring Allogeneic Stem Cell Transplantation
Condition:
  • Chronic Lymphocytic Leukemia
  • Richter`s Transformation
    • Date: 2017-05-12
    Interventions: Biological: Obinutuzumab Obinutuzumab i.v.: 100 mg, 900 mg, 1000 mg
Completed Study Name: VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
Condition:
  • Leukemia
  • Lymphoma

Date: 2006-03-15
Interventions: Drug: laromustine
Next >>>